Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
403
Employees403
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
403
Employees403

NTLA Key Statistics

Market cap
1.59B
Market cap1.59B
Price-Earnings ratio
-5.46
Price-Earnings ratio-5.46
Dividend yield
Dividend yield
Average volume
9.61M
Average volume9.61M
High today
$26.25
High today$26.25
Low today
$9.72
Low today$9.72
Open price
$13.76
Open price$13.76
Volume
52.50M
Volume52.50M
52 Week high
$28.25
52 Week high$28.25
52 Week low
$5.90
52 Week low$5.90

NTLA News

TipRanks 1h
Intellia Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo downgraded Intellia Therapeutics (NTLA) to Equal Weight from Overweight with a price target of $17, down from $45. Given the occurrence of the Hy’s...

TipRanks 4h
Intellia Therapeutics’ Long-Term Study of NTLA-2001: What Investors Need to Know

Intellia Therapeutics Inc ((NTLA)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

TipRanks 4h
Intellia Therapeutics downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Intellia Therapeutics (NTLA) to Market Perform from Outperform after the company announced that it has voluntarily paused enrollment an...

Analyst ratings

73%

of 26 ratings
Buy
73.1%
Hold
23.1%
Sell
3.8%

More NTLA News

Nasdaq 5h
Intellia Therapeutics Plunges 44% After Update On Magnitude Clinical Trials

(RTTNews) - Intellia Therapeutics, Inc. (NTLA) fell 43.79% to $14.39, down $11.21, after providing an update on its Magnitude Phase 1/2 clinical trials evaluati...

Intellia Therapeutics Plunges 44% After Update On Magnitude Clinical Trials
TipRanks 7h
Intellia Therapeutics downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Debjit Chattopadhyay downgraded Intellia Therapeutics (NTLA) to Neutral from Buy. Published first on TheFly – the ultimate source for real-t...

Sherwood News 8h
Intellia tanks as it pauses late-stage CRISPR gene-editing trials after one patient was hospitalized

Intellia tanks as it pauses late-stage CRISPR gene-editing trials after one patient was hospitalized Intellia dropped sharply on Monday after it announced that...

Intellia tanks as it pauses late-stage CRISPR gene-editing trials after one patient was hospitalized
TipRanks 8h
Mitchell Kapoor Maintains Buy Rating on Intellia Therapeutics Despite Market Overreaction to Phase 3 Trial Pause

In a report released today, Mitchell Kapoor from H.C. Wainwright maintained a Buy rating on Intellia Therapeutics, with a price target of $25.00. Elevate Your I...

TipRanks 8h
Intellia Therapeutics price target lowered to $30 from $36 at BofA

BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $36 and keeps a Buy rating on the shares after the company paused dosing and sc...

Benzinga 9h
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

Intellia Therapeutics Inc. (NASDAQ:NTLA) shares tumbled after the company said it had temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE a...

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
TipRanks 11h
Why Is Intellia Therapeutics Down 45% Today?

Intellia Therapeutics (NTLA) stock plummeted on Monday after the biotechnology company announced an update from its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical t...

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.